文献速递淋巴瘤造血干细胞移植与细胞治疗MDS 与骨髓增殖性肿瘤

丹麦淋巴瘤患者接受大剂量化疗和自体造血干细胞移植后的第二原发恶性肿瘤:一项基于人群的回顾性队列研究

Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study.
PubMed 文献 · Lancet Haematol · 2023-09-06

该研究基于丹麦淋巴瘤登记处数据,纳入2001年1月1日至2017年12月31日期间接受大剂量化疗和自体造血干细胞移植的18岁及以上侵袭性淋巴瘤患者803例,并按1:5匹配一般人群对照4015例。中位随访7.76年,患者第二原发恶性肿瘤发生率高于对照(调整HR 2.35,95%CI 1.93-2.87,p<0.0001),10年累积风险20% vs 14%。

要点

  • 接受大剂量化疗和自体HSCT的淋巴瘤患者第二原发恶性肿瘤发生率高于匹配对照(调整HR 2.35)。
  • 非黑色素瘤皮肤癌和MDS/AML发生率显著升高,实体瘤发生率无显著差异。
  • 10年第二原发恶性肿瘤累积风险患者为20%,对照为14%。

核心结论

  • 大剂量化疗和自体HSCT与淋巴瘤患者非黑色素瘤皮肤癌及MDS或AML风险增加相关,但与实体瘤风险增加无关。
  • 这些发现对未来在该情形下选择大剂量化疗和自体HSCT与嵌合抗原受体T细胞治疗时的个体化风险-获益评估具有相关性。

研究设计与样本

  • 回顾性、基于人群的队列研究,纳入丹麦淋巴瘤登记处2001年1月1日至2017年12月31日期间接受大剂量化疗和自体HSCT的18岁及以上侵袭性淋巴瘤患者。
  • 患者按出生年份和性别以1:5匹配丹麦民事登记系统的一般人群对照。
  • 纳入标准为有登记的自体HSCT日期,排除原发性中枢神经系统淋巴瘤;患者和匹配对照均排除HIV感染、器官移植或纳入前其他恶性肿瘤。
  • 共评估910例淋巴瘤患者,纳入803例(537例[67%]男性,266例[33%]女性);纳入4015例匹配对照(2685例[67%]男性,1330例[33%]女性)。
  • 中位随访7.76年(IQR 4.77-11.73)。

主要发现

  • 接受大剂量化疗和自体HSCT的患者第二原发恶性肿瘤发生率高于匹配对照(调整HR 2.35,95%CI 1.93-2.87,p<0.0001)。
  • 患者非黑色素瘤皮肤癌发生率高于匹配对照(HR 2.94,95%CI 2.10-4.11,p<0.0001)。
  • 患者MDS或AML发生率高于匹配对照(HR 41.13,95%CI 15.77-107.30,p<0.0001)。
  • 患者实体瘤发生率与匹配对照无显著差异(HR 1.21,95%CI 0.89-1.64,p=0.24)。
  • 10年第二原发恶性肿瘤累积风险患者为20%(95%CI 17-23),匹配对照为14%(95%CI 13-15)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Second primary malignancies (SPMs) are known complications after chemotherapy, but the risk is not well characterised for patients with lymphoma treated with high-dose chemotherapy and autologous haematopoietic stem-cell transplantation (HSCT). We aimed to investigate the rate of SPMs in this population relative to matched control individuals from the general population. METHODS: In this retrospective, population-based cohort study, patients aged 18 years or older with an aggressive lymphoma who received high-dose chemotherapy and autologous HSCT in Denmark between Jan 1, 2001, and Dec 31, 2017, were included from the Danish Lymphoma Registry and matched (1:5) to control individuals from the general population on birth year and sex via the Danish Civil Registration System. Patients were eligible if they had a registered date of autologous HSCT and patients with primary CNS lymphoma were excluded. Exclusion criteria for both patients and matched control individuals were HIV infection, organ transplantation, or other malignancies before inclusion. The key endpoint was the incidence of SPMs assessed in all study participants. The effect of treatment on SPMs was also investigated in patients who were followed up from first lymphoma diagnosis, with high-dose chemotherapy and autologous HSCT as a time-dependent exposure. FINDINGS: Of 910 patients with lymphoma assessed, 803 were included (537 [67%] were male and 266 [33%] were female); 4015 matched control individuals were included (2685 [67%] were male and 1330 [33%] were female). Ethnicity data were not available. Median follow-up was 7·76 years (IQR 4·77-11·73). The SPM rate was higher among patients receiving high-dose chemotherapy and autologous HSCT than matched control individuals (adjusted hazard ratio [HR] 2·35, 95% CI 1·93-2·87, p<0·0001). Patients receiving high-dose chemotherapy and autologous HSCT had a higher rate of non-melanoma skin cancer (2·94, 2·10-4·11, p<0·0001) and of myelodysplastic syndrome or acute myeloid leukaemia (AML; 41·13, 15·77-107·30, p<0·0001) than matched control individuals, but there was no significant difference in the rate of solid tumours (1·21, 0·89-1·64, p=0·24). The cumulative risk of SPMs at 10 years was 20% (95% CI 17-23) in patients compared with 14% (13-15) in matched control individuals. High-dose chemotherapy and autologous HSCT was associated with an increased risk of SPMs when analysed as a time-dependent exposure from first lymphoma diagnosis (adjusted HR 1·58, 95% CI 1·14-2·17, p=0·0054). INTERPRETATION: High-dose chemotherapy and autologous HSCT was associated with an increased risk of non-melanoma skin cancer and myelodysplastic syndrome or AML but not with increased risk of solid tumours in patients treated for lymphoma. These findings are relevant for future individualised risk-benefit assessments when choosing between high-dose chemotherapy and autologous HSCT and chimeric antigen receptor T-cell therapy in this setting. FUNDING: Danish Cancer Society.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Trab T, Baech J, Jakobsen LH, et al. Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study. Lancet Haematol. 2023. PMID: 37689081. doi:10.1016/S2352-3026(23)00212-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。